Biotech | August 08, 2021
Strides Pharma reports Q1FY22 consolidated loss at Rs 205.2 Cr
The company expects revenue growth of 10-15 per cent in the US
The company expects revenue growth of 10-15 per cent in the US
PAT rises to Rs 195.76 crore
India business contributes to a stellar performance
Forex gains stood at Rs 20 crore for the quarter
Total income grew in the quarter
EPS climbs to Rs 9.25 for the quarter
Aditya Puri former MD of HDFC bank joins Solara board as chairman
Nureca Ltd has reported financial results for the period ended June 30, 2021.
The company posted net profit of Rs.19.36 crores for the period ended June 30, 2020.
The Phase III clinical trial for NONS is expected to be completed by Q4 2021.
Subscribe To Our Newsletter & Stay Updated
